Large-scale genome editing of primary human natural killer (NK) cells: A quest toward manufacture of clinically relevant CAR NK cells
Sponsor
NK cells are effector lymphocytes of the innate immune system that control several types of tumors and microbial infections by limiting their spread and subsequent tissue damage. Genetically engineered primary human NK cells for clinical immuno-oncology applications hold great promise due to their potent antitumor properties and demonstrated safety in an allogeneic setting.
One of the key challenges faced by the cell therapy industry is the expansion and editing of NK cells using conventional methods. In this presentation, we will discuss how various cell therapy products developed by Thermo Fisher Scientific, including the Cell Therapy Systems™ (CTS) Xenon™ Electroporation System and CTS TrueCut™ Cas9 Protein, enable the generation, expansion, and processing of large numbers of functionally viable human CAR NK cells.
We will present data demonstrating successful engineering of CAR NK cells at clinical scale as measured by knock-out efficiency, anti-Meso3 knock-in, post-editing phenotype, viability, expansion over 3 weeks, and functionality shown by cytotoxicity in a cancer cell model.
Attend this webinar to discover:
- The potential of genetically modified NK cells in a clinical cell therapy setting
- Expected post-electroporation viability, phenotypic profile, proliferation ability, and cytotoxic effects of CAR NK cells in a typical gene editing workflow
- Available GMP-compliant tools to support genetic modification, processing, and expansion of primary human NK cells
SPEAKERS
You might also like
Clinical-scale non-viral gene edited CAR-NK cells for cell therapy
Enabling allogeneic cell therapy development: scaling up generation of PSC-derived NK cells
Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies
Mastering allogeneic NK cell therapies: flexibility, robustness, and speed to clinic
